Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Vor Biopharma Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

BOSTON, DEC. 15, 2025 (GLOBE NEWSWIRE) -- VOR BIO (NASDAQ: VOR), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY TRANSFORMING THE TREATMENT OF AUTOIMMUNE DISEASES, ANNOUNCED TODAY THAT IT HAS ENTERED INTO A SECURITIES PURCHASE AGREEMENT TO SELL 13,876,032 SHARES OF ITS COMMON STOCK AT A PRICE OF $10.81 PER SHARE TO A SELECT GROUP OF INSTITUTIONAL AND ACCREDITED HEALTHCARE SPECIALIST INVESTORS IN A PRIVATE PLACEMENT. VOR BIO ANTICIPATES THE GROSS PROCEEDS FROM THE PRIVATE PLACEMENT TO BE APPROXIMATELY $150 MILLION, BEFORE DEDUCTING ANY OFFERING-RELATED EXPENSES. VOR BIO DID NOT ENGAGE A PLACEMENT AGENT IN CONNECTION WITH THE PRIVATE PLACEMENT. THE PRIVATE PLACEMENT IS EXPECTED TO CLOSE ON OR ABOUT DECEMBER 18, 2025, SUBJECT TO THE SATISFACTION OF CUSTOMARY CLOSING CONDITIONS.

VOR BIO ANNOUNCES $150 MILLION PRIVATE PLACEMENT

MULTIPLE LATE-STAGE DATA READOUTS REINFORCE TELITACICEPT'S BROAD POTENTIAL ACROSS AUTOIMMUNE DISEASES EXPANSION OF EXECUTIVE LEADERSHIP AND BOARD STRENGTHENS GLOBAL DEVELOPMENT CAPABILITIES

VOR BIO REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BOSTON, NOV. 10, 2025 (GLOBE NEWSWIRE) -- VOR BIOPHARMA INC. (NASDAQ: VOR), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DEDICATED TO TRANSFORMING THE TREATMENT OF AUTOIMMUNE DISEASES, TODAY ANNOUNCED THE PRICING OF AN UNDERWRITTEN PUBLIC OFFERING OF 10,000,000 SHARES OF ITS COMMON STOCK AT A PUBLIC OFFERING PRICE OF $10.00 PER SHARE. THE GROSS PROCEEDS FROM THE OFFERING ARE EXPECTED TO BE $100 MILLION, BEFORE DEDUCTING THE UNDERWRITING DISCOUNTS AND COMMISSIONS AND OFFERING EXPENSES. THE OFFERING IS EXPECTED TO CLOSE ON OR ABOUT NOVEMBER 12, 2025, SUBJECT TO CUSTOMARY CLOSING CONDITIONS. IN ADDITION, VOR BIO HAS GRANTED THE UNDERWRITERS A 30-DAY OPTION TO PURCHASE UP TO AN ADDITIONAL 1,500,000 SHARES OF ITS COMMON STOCK AT THE PUBLIC OFFERING PRICE, LESS UNDERWRITING DISCOUNTS AND COMMISSIONS. ALL OF THE SHARES ARE BEING SOLD BY VOR BIO.

VOR BIO ANNOUNCES PRICING OF PUBLIC OFFERING OF $100 MILLION OF COMMON STOCK

BOSTON, NOV. 10, 2025 (GLOBE NEWSWIRE) -- VOR BIOPHARMA INC. (NASDAQ: VOR) (VOR BIO), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DEDICATED TO TRANSFORMING THE TREATMENT OF AUTOIMMUNE DISEASES, TODAY ANNOUNCED THAT IT HAS COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF $100 MILLION OF SHARES OF ITS COMMON STOCK. IN ADDITION, VOR BIO INTENDS TO GRANT THE UNDERWRITERS A 30-DAY OPTION TO PURCHASE UP TO AN ADDITIONAL $15 MILLION OF SHARES OF ITS COMMON STOCK AT THE PUBLIC OFFERING PRICE, LESS UNDERWRITING DISCOUNTS AND COMMISSIONS.

VOR BIO ANNOUNCES PROPOSED PUBLIC OFFERING OF $100 MILLION OF COMMON STOCK

TREATMENT WITH TELITACICEPT FOR 39 WEEKS RESULTED IN A RAPID, CLINICALLY MEANINGFUL, AND STATISTICALLY SIGNIFICANT REDUCTION IN PROTEINURIA, WITH A FAVORABLE SAFETY PROFILE

TELITACICEPT ACHIEVED PRIMARY ENDPOINT OF REDUCING PROTEINURIA IN STAGE A OF A PHASE 3 CLINICAL STUDY FOR IGA NEPHROPATHY IN CHINA

BOSTON, NOV. 07, 2025 (GLOBE NEWSWIRE) -- VOR BIO (NASDAQ: VOR), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY TRANSFORMING THE TREATMENT OF AUTOIMMUNE DISEASES, TODAY ANNOUNCED THAT IT WILL PARTICIPATE IN THE FOLLOWING UPCOMING INVESTOR CONFERENCES: TDCOWEN VIRTUALIMMUNOLOGY & INFLAMMATION SUMMIT FIRESIDE CHAT: WEDNESDAY, NOVEMBER 12, 2025, AT 2:30PM ET 8TH ANNUAL EVERCORE HEALTHCARE CONFERENCE FIRESIDE CHAT: TUESDAY, DECEMBER 2, 2025, 3:00PM ETLOCATION: MIAMI, FL A LIVE WEBCAST AND ARCHIVED REPLAY OF THE FIRESIDE CHATS WILL BE AVAILABLE ON THE INVESTORS SECTION OF WWW.VORBIO.COM. ABOUT VOR BIO VOR BIO IS A CLINICAL-STAGE BIOTECHNOLOGY COMPANY TRANSFORMING THE TREATMENT OF AUTOIMMUNE DISEASES.

VOR BIO TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

BOSTON, NOV. 03, 2025 (GLOBE NEWSWIRE) -- VOR BIO (NASDAQ: VOR), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY TRANSFORMING THE TREATMENT OF AUTOIMMUNE DISEASES, TODAY ANNOUNCED THE APPOINTMENT OF JEREMY SOKOLOVE, M.D., AS CHIEF MEDICAL OFFICER.

VOR BIO APPOINTS JEREMY SOKOLOVE, M.D. AS CHIEF MEDICAL OFFICER

BOSTON, OCT. 31, 2025 (GLOBE NEWSWIRE) -- VOR BIO (NASDAQ: VOR), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY TRANSFORMING THE TREATMENT OF AUTOIMMUNE DISEASES, TODAY ANNOUNCED THAT, ON OCTOBER 15, 2025, THE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS GRANTED STOCK OPTIONS TO PURCHASE AN AGGREGATE OF 113,478 SHARES OF VOR BIO'S COMMON STOCK AND RESTRICTED STOCK UNITS (RSUS) REPRESENTING THE RIGHT TO RECEIVE AN AGGREGATE OF 24,319 SHARES OF VOR BIO'S COMMON STOCK TO 20 NEWLY HIRED EMPLOYEES. THE FOREGOING STOCK OPTIONS AND RSUS WERE GRANTED AS MATERIAL INDUCEMENTS TO EMPLOYMENT WITH VOR BIO IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4) AND WERE GRANTED UNDER THE VOR BIOPHARMA INC. 2023 INDUCEMENT PLAN (THE INDUCEMENT PLAN).

VOR BIO REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

TELITACICEPT DELIVERED CONSISTENT QUALITY-OF-LIFE IMPROVEMENT ACROSS BOTH TREATMENT AND PLACEBO CROSSOVER ARMS 100% OF PATIENTS ON TELITACICEPT FOR 48 WEEKS ACHIEVED 2-POINT MYASTHENIA GRAVIS ACTIVITIES OF DAILY LIVING (MG-ADL) IMPROVEMENT, WITH A MEAN REDUCTION OF -7.5 POINTS SUSTAINED EFFICACY AND FAVORABLE SAFETY EXTENSION DATA SUPPORT POTENTIAL GLOBAL BEST-IN-DISEASE PROFILE IN GENERALIZED MYASTHENIA GRAVIS (GMG) BOSTON, OCT. 29, 2025 (GLOBE NEWSWIRE) -- VOR BIO (NASDAQ: VOR), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY TRANSFORMING THE TREATMENT OF AUTOIMMUNE DISEASES, TODAY ANNOUNCED THAT ITS COLLABORATOR, REMEGEN CO., LTD (HKEX: 9995, SHA: 688331), PRESENTED 48-WEEK OPEN-LABEL EXTENSION (OLE) DATA FROM ITS PHASE 3 STUDY IN CHINA EVALUATING TELITACICEPT IN PATIENTS WITH GMG. THE RESULTS WILL BE PRESENTED IN A LATE-BREAKING SESSION ON OCTOBER 29 AT 10:50AM PT AT THE AMERICAN ASSOCIATION OF NEUROMUSCULAR & ELECTRODIAGNOSTIC MEDICINE (AANEM) ANNUAL MEETING.

TELITACICEPT DEMONSTRATES SUSTAINED EFFICACY AND FAVORABLE SAFETY PROFILE IN 48-WEEK CHINA PHASE 3 OPEN-LABEL EXTENSION GENERALIZED MYASTHENIA GRAVIS DATA

CAMBRIDGE, MASS., OCT. 22, 2025 (GLOBE NEWSWIRE) -- VOR BIO (NASDAQ: VOR), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY TRANSFORMING THE TREATMENT OF AUTOIMMUNE DISEASES, ANNOUNCED TODAY THAT IT WILL HOST A LIVE WEBCAST TO PRESENT AND DISCUSS THE NEWLY DISCLOSED, LATE-BREAKING 48-WEEK PHASE 3 CLINICAL DATA IN CHINA FOR TELITACICEPT IN PRIMARY SJGREN'S DISEASE. THE STUDY WAS CONDUCTED BY VOR BIO'S COLLABORATOR REMEGEN CO., LTD (HKEX: 9995, SHA: 688331).

Vor Biopharma Inc.

VOR

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Vor Biopharma Inc.

VOR.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

VOR